10/18/2011

A trial of more than 8,000 patients led by New York University School of Medicine researchers found bivalirudin administered during PCI saw a decreased bleeding risk compared with the use of heparin or heparin combined with glycoprotein IIb-IIIa inhibitors. Researchers also found no increase in thrombotic or ischemic issues in the 12 months following PCI where bivalirudin was used. The results were published in the journal Circulation: Cardiovascular Interventions.

Related Summaries